BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 26261104)

  • 1. Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP).
    Stacchiotti S; Pantaleo MA; Negri T; Astolfi A; Tazzari M; Dagrada GP; Urbini M; Indio V; Maestro R; Gronchi A; Fiore M; Dei Tos AP; Conca E; Palassini E; Vincenzi B; Grosso F; Pilotti S; Castelli C; Casali PG
    Clin Cancer Res; 2016 Feb; 22(4):837-46. PubMed ID: 26261104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation.
    Rutkowski P; Klimczak A; Ługowska I; Jagielska B; Wągrodzki M; Dębiec-Rychter M; Pieńkowska-Grela B; Świtaj T
    Eur J Surg Oncol; 2017 Jun; 43(6):1134-1141. PubMed ID: 28365129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment.
    Tazzari M; Indio V; Vergani B; De Cecco L; Rini F; Negri T; Camisaschi C; Fiore M; Stacchiotti S; Dagrada GP; Casali PG; Gronchi A; Astolfi A; Pantaleo MA; Villa A; Lombardo C; Arienti F; Pilotti S; Rivoltini L; Castelli C
    J Invest Dermatol; 2017 Feb; 137(2):484-493. PubMed ID: 27608549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients.
    Wang C; Luo Z; Chen J; Zheng B; Zhang R; Chen Y; Shi Y
    Medicine (Baltimore); 2015 May; 94(17):e773. PubMed ID: 25929918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of metastatic fibrosarcomatous dermatofibrosarcoma protuberans with imatinib mesylate.
    Kambayashi Y; Kasahara Y; Ohuchi K; Amagai R; Hashimoto A; Asano Y; Fujimura T
    Dermatol Ther; 2022 Oct; 35(10):e15736. PubMed ID: 35898161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
    McArthur GA; Demetri GD; van Oosterom A; Heinrich MC; Debiec-Rychter M; Corless CL; Nikolova Z; Dimitrijevic S; Fletcher JA
    J Clin Oncol; 2005 Feb; 23(4):866-73. PubMed ID: 15681532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib.
    Stacchiotti S; Pedeutour F; Negri T; Conca E; Marrari A; Palassini E; Collini P; Keslair F; Morosi C; Gronchi A; Pilotti S; Casali PG
    Int J Cancer; 2011 Oct; 129(7):1761-72. PubMed ID: 21128251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.
    Maki RG; Awan RA; Dixon RH; Jhanwar S; Antonescu CR
    Int J Cancer; 2002 Aug; 100(6):623-6. PubMed ID: 12209598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.
    Ugurel S; Mentzel T; Utikal J; Helmbold P; Mohr P; Pföhler C; Schiller M; Hauschild A; Hein R; Kämpgen E; Kellner I; Leverkus M; Becker JC; Ströbel P; Schadendorf D
    Clin Cancer Res; 2014 Jan; 20(2):499-510. PubMed ID: 24173542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dermatofibrosarcoma protuberans with fibrosarcomatous transformation: a case report.
    Hrudka J; Charvát M; Grossmann P; Kinkor Z
    Cesk Patol; 2020; 56(2):89-93. PubMed ID: 32493025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib Treatment for Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans: A Systematic Review.
    Navarrete-Dechent C; Mori S; Barker CA; Dickson MA; Nehal KS
    JAMA Dermatol; 2019 Mar; 155(3):361-369. PubMed ID: 30601909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of gene mutations in three cases of dermatofibrosarcoma protuberans (DFSP): ordinary DFSP, DFSP with fibrosarcomatous lesion (DFSP-FS) and lung metastasis of DFSP-FS.
    Saeki H; Hoashi T; Tada Y; Ashida R; Kuwano Y; Le Pavoux A; Tsunemi Y; Shikada J; Torii H; Kawabata Y; Kikuchi K; Tamada Y; Matsumoto Y; Tamaki K
    J Dermatol Sci; 2003 Dec; 33(3):161-7. PubMed ID: 14643521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans.
    Eilers G; Czaplinski JT; Mayeda M; Bahri N; Tao D; Zhu M; Hornick JL; Lindeman NI; Sicinska E; Wagner AJ; Fletcher JA; Mariño-Enriquez A
    Mol Cancer Ther; 2015 Jun; 14(6):1346-53. PubMed ID: 25852058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COL1A1-PDGFB fusion transcripts in fibrosarcomatous areas of six dermatofibrosarcomas protuberans.
    Wang J; Morimitsu Y; Okamoto S; Hisaoka M; Ishida T; Sheng W; Hashimoto H
    J Mol Diagn; 2000 Feb; 2(1):47-52. PubMed ID: 11272901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans--a case report.
    Lemm D; Muegge LO; Hoeffken K; Aklan T; Mentzel T; Thorwarth M; Schultze-Mosgau S
    Oral Maxillofac Surg; 2008 Dec; 12(4):209-13. PubMed ID: 18751744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PDGFB rearrangement in dermatofibrosarcoma protuberans: correlation with clinicopathologic characteristics and clinical implications.
    Ha SY; Lee SE; Kwon MJ; Kim YJ; Lee EH; Seo J; Jang KT; Lee J; Choi YL
    Hum Pathol; 2013 Jul; 44(7):1300-9. PubMed ID: 23347652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.
    Rutkowski P; Van Glabbeke M; Rankin CJ; Ruka W; Rubin BP; Debiec-Rychter M; Lazar A; Gelderblom H; Sciot R; Lopez-Terrada D; Hohenberger P; van Oosterom AT; Schuetze SM; ;
    J Clin Oncol; 2010 Apr; 28(10):1772-9. PubMed ID: 20194851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients.
    Kérob D; Porcher R; Vérola O; Dalle S; Maubec E; Aubin F; D'Incan M; Bodokh I; Boulinguez S; Madelaine-Chambrin I; Mathieu-Boue A; Servant JM; de Kerviler E; Janin A; Calvo F; Pedeutour F; Lebbe C
    Clin Cancer Res; 2010 Jun; 16(12):3288-95. PubMed ID: 20439456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of fibrosarcomatous transformation in dermatofibrosarcoma protuberans: a cohort study.
    Hoesly PM; Lowe GC; Lohse CM; Brewer JD; Lehman JS
    J Am Acad Dermatol; 2015 Mar; 72(3):419-25. PubMed ID: 25582537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Imatinib Mesylate Treatment in a Patient with Dermatofibrosarcoma Protuberans with Pulmonary and Pancreatic Metastases.
    Tatai T; Gomi D; Fukushima T; Kobayashi T; Sekiguchi N; Sakamoto A; Sasaki S; Koizumi T; Sano K
    Intern Med; 2016; 55(17):2507-11. PubMed ID: 27580559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.